The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …
[HTML][HTML] Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
V Leko, SA Rosenberg - Cancer Cell, 2020 - cell.com
Cancer elimination in humans can be achieved with immunotherapy that relies on T
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
lymphocyte-mediated recognition of tumor antigens. Several types of these antigens have …
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central
to antitumour immune responses,–; however, the relationship between phenotypic …
to antitumour immune responses,–; however, the relationship between phenotypic …
The emerging landscape of immune cell therapies
Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …
immune cell therapies are among the most advanced, having already demonstrated …
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
In this Timeline, we describe the characteristics of tumour antigens that are recognized by
spontaneous T cell responses in cancer patients and the paths that led to their identification …
spontaneous T cell responses in cancer patients and the paths that led to their identification …
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
S Simon, N Labarriere - Oncoimmunology, 2018 - Taylor & Francis
Inhibitory properties of PD-1 receptor engagement on activated T cells are well established
in physiologic and pathological contexts. In cancer, the use of checkpoint blockade, such as …
in physiologic and pathological contexts. In cancer, the use of checkpoint blockade, such as …
Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma
Intratumoral dendritic cells (DC) bearing CD103 in mice or CD141 in humans drive
intratumoral CD8+ T cell activation. Using multiple strategies, we identified a critical role for …
intratumoral CD8+ T cell activation. Using multiple strategies, we identified a critical role for …
Monoclonal TCR-redirected tumor cell killing
N Liddy, G Bossi, KJ Adams, A Lissina, TM Mahon… - Nature medicine, 2012 - nature.com
T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a
minority of patients with cancer. In the majority of these individuals, however, there is a …
minority of patients with cancer. In the majority of these individuals, however, there is a …
Therapeutic cancer vaccines: past, present, and future
Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …
to treat late stage disease by using a patient's own immune system. The promising results …
Immune targets and neoantigens for cancer immunotherapy and precision medicine
RF Wang, HY Wang - Cell research, 2017 - nature.com
Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …